Veph1 Antibody

What is VEPH1 and why is it significant for antibody-based detection in cancer research?

VEPH1 is among genes located on chromosome 3q24-26, a region frequently amplified in several cancer types. Its Drosophila ortholog, Melted, plays roles in neural and eye development, metabolism, and size determination through effects on multiple signaling pathways. VEPH1 has been identified as a potent inhibitor of transforming growth factor-β (TGF-β) signaling, interacting with TGF-β type I receptor (TβRI) and inhibiting the dissociation of activated SMAD2 from TβRI .

Detecting VEPH1 expression via antibody-based methods is particularly relevant because:

• VEPH1 locus is amplified in 17.3% of ovarian serous cystadenocarcinomas

• Amplification patterns vary across cancer types, including cervical, lung squamous cell, esophageal, and head and neck cancers

• Expression levels correlate with invasive phenotypes in certain cancer cell lines

Research methodology: For accurate detection of VEPH1 in tissue samples, immunohistochemistry using specific antibodies (such as ab121875, dilution 1:20) combined with high-pressure antigen retrieval and DAB visualization has been successfully employed .

What are the recommended controls when using VEPH1 antibodies in expression studies?

When studying VEPH1 expression patterns using antibody-based detection methods:

Positive controls:

• OVCA429, ES2, and HEY cell lines demonstrably express high levels of VEPH1 protein and can serve as reliable positive controls

• Paraffin-embedded cutaneous melanoma tissues with confirmed VEPH1 expression

Negative controls:

• SKOV3, OVCAR3, and HOC7 cells show little to no VEPH1 expression

• HepG2 human epithelial hepatocarcinoma cells and COS7 African green monkey kidney fibroblasts lack detectable VEPH1 expression

• Primary antibody omission controls to verify staining specificity

When evaluating immunohistochemistry results, consider that positive VEPH1 expression is typically defined when >10% of counted cells show positive staining .

How does VEPH1 subcellular localization influence antibody selection and staining protocols?

VEPH1 protein is predominantly localized to the cell membrane, as demonstrated by immunofluorescent imaging of EGFP-tagged VEPH1 in HepG2 cells . This membrane localization is consistent with the subcellular distribution reported for its Drosophila ortholog Melted in wing-disk cells.

Methodological considerations:

• Select antibodies validated for membrane protein detection

• Optimize fixation protocols to preserve membrane integrity (brief fixation times with paraformaldehyde)

• Include membrane permeabilization steps calibrated to maintain epitope accessibility without excessive disruption

• Use confocal microscopy with z-stack analysis to accurately distinguish membrane from cytoplasmic staining

• Consider dual immunofluorescence with established membrane markers for colocalization studies

This membrane localization pattern provides an important quality control parameter when validating new VEPH1 antibodies or optimizing immunostaining protocols.

How can VEPH1 antibodies be optimized for studying TGF-β pathway modulation?

VEPH1 has been established as a negative modulator of canonical TGF-β signaling, making antibody-based detection crucial for understanding this regulatory mechanism. Advanced research protocols include:

Methodological approach for detecting VEPH1-TGF-β pathway interactions:

• Co-immunoprecipitation using VEPH1 antibodies to isolate protein complexes

• Western blot analysis to detect TβRI association with VEPH1

• Proximity ligation assays to visualize in situ VEPH1-TβRI interactions

• Immunofluorescence co-localization studies with TGF-β pathway components

Research findings demonstrate that VEPH1 impedes release of activated SMAD2 from TβRI, resulting in reduced nuclear accumulation of activated SMAD2 and diminished TGF-β-induced gene responses . When optimizing antibody-based detection of these interactions, researchers should consider the transient nature of these protein complexes and implement appropriate crosslinking strategies.

What are the optimal conditions for using VEPH1 antibodies in phospho-SMAD detection assays?

When studying VEPH1's impact on SMAD phosphorylation and trafficking, researchers should consider:

Experimental design recommendations:

• Use paired antibodies against both total and phosphorylated SMAD2/3

• Include time-course experiments (highest ID1 protein levels observed at 1.5h post-TGF-β treatment)

• Monitor SMAD7 transcript levels (peak at 1h post-TGF-β treatment) as a functional readout

• Compare nuclear vs. cytoplasmic fractions to assess SMAD translocation

Research data show that VEPH1 expression decreases TGF-β-induced ID1 protein levels across all examined time points and reduces TGF-β-stimulated PAI-1 and SMAD7 transcript upregulation (from 4.6-fold to 2.8-fold for PAI-1 and from 2.4-fold to 1.9-fold for SMAD7) .

How can VEPH1 antibodies be utilized in EMT research?

Epithelial-mesenchymal transition (EMT) is a critical process in cancer progression that can be modulated by VEPH1 expression. When designing antibody-based experiments:

Technical protocol recommendations:

• Implement multiplex immunofluorescence to simultaneously detect VEPH1 and EMT markers

• Combine with RT-qPCR validation of EMT-related gene expression

• Correlate VEPH1 staining patterns with E-cadherin/N-cadherin ratios

• Use VEPH1 knockdown/overexpression models as comparative controls

Research evidence indicates that cells overexpressing VEPH1 show diminished expression of EMT markers (N-cadherin, Vimentin) and increased E-cadherin expression, accompanied by decreased cell proliferation, migration, invasion, and inhibited cell cycle progression . This makes VEPH1 antibody detection particularly valuable in tracking EMT status in cancer models.

Why might Western blot detection of VEPH1 show inconsistent results across different cancer samples?

When researchers encounter variability in VEPH1 detection across cancer samples, several factors should be considered:

Common challenges and solutions:

• Varied expression levels: VEPH1 exhibits differential expression across cancer types and cell lines. For example, high levels were detected in OVCA429, ES2, and HEY cells, while SKOV3, OVCAR3, and HOC7 cells showed minimal expression .

• Protein size verification: Ensure antibodies recognize the correct molecular weight band to avoid false positives.

• Extraction protocol optimization: VEPH1's membrane localization requires appropriate lysis buffers containing adequate detergents to solubilize membrane-associated proteins.

• Phosphorylation state: Since VEPH1 interacts with phosphorylation-dependent signaling pathways, consider using phosphatase inhibitors in lysate preparation.

• Antibody validation: Cross-validate results using multiple VEPH1 antibodies targeting different epitopes.

Additionally, researchers should note that genomic analyses reveal varying amplification rates of the VEPH1 locus across cancer types, which may contribute to expression differences .

What are the best validation strategies for confirming VEPH1 antibody specificity?

To ensure VEPH1 antibody specificity and minimize false results:

Recommended validation protocol:

• siRNA knockdown experiments using at least two different siRNA sequences (as demonstrated with siVEPH1 nos. 1 and 2)

• Overexpression controls using VEPH1 expression constructs

• Peptide competition assays to confirm epitope specificity

• Comparison of staining patterns across multiple antibodies targeting different VEPH1 regions

• Mass spectrometry validation of immunoprecipitated proteins

Research evidence shows that silencing VEPH1 expression with specific siRNAs increases TGF-β-induced SMAD7 transcripts relative to controls, providing a functional validation approach for antibody specificity .

How can VEPH1 antibodies contribute to understanding cancer subtype classification?

VEPH1 expression patterns may serve as valuable biomarkers for cancer stratification:

Methodological approach:

• Tissue microarray analysis with VEPH1 antibodies across cancer cohorts

• Correlation of VEPH1 immunostaining with clinicopathological features

• Integration with genomic data on 3q24-26 amplification status

• Multivariate analysis combining VEPH1 with other TGF-β pathway markers

Research findings indicate that VEPH1 expression varies significantly across ovarian cancer subtypes, with expression in aggressive cell lines like OVCA429 and HEY (derived from serous adenocarcinomas) showing more invasive phenotypes than cell lines lacking VEPH1 expression . This suggests VEPH1 detection could contribute to identifying more aggressive cancer subtypes.

What techniques can optimize VEPH1 antibody usage in studying protein-protein interactions?

For researchers investigating VEPH1's interactome:

Advanced methodological approaches:

• LUMIER assays: Semiquantitative luminescence-based immunoprecipitation assays can quantify the impact of VEPH1 on transient protein interactions, such as SMAD2-TβRI .

• Proximity-dependent biotinylation: BioID or TurboID fusions with VEPH1 can identify proximal interacting proteins.

• Fluorescence resonance energy transfer (FRET): For studying VEPH1-TβRI interactions in living cells.

• Sequential co-immunoprecipitation: To isolate specific VEPH1-containing complexes.

Research data demonstrate that VEPH1 induces a dose-dependent increase in SMAD2 interaction with constitutively active TβRI(TD) . Moreover, the SMAD2 retained at TβRI in the presence of VEPH1 is phosphorylated at the C-terminus, indicating that VEPH1 specifically impedes the release of activated SMAD2 rather than its phosphorylation .

How should researchers approach VEPH1 antibody selection for studying its dual roles in cancer?

VEPH1 exhibits context-dependent roles across cancer types, requiring careful antibody selection:

Strategic considerations:

• Cancer type specificity: Select antibodies validated in the specific cancer type under investigation. VEPH1 is lowly expressed in cutaneous melanoma but amplified in ovarian cancer .

• Epitope accessibility: Consider whether VEPH1 interactions with TGF-β receptors might mask certain epitopes, potentially necessitating multiple antibodies targeting different regions.

• Post-translational modifications: Since VEPH1 functions within signaling pathways, modification-specific antibodies may reveal regulatory mechanisms.

• Functional domains: Target antibodies to regions involved in specific protein interactions to distinguish different functional pools of VEPH1.

Research findings suggest that VEPH1 may contribute to carcinogenesis by blocking canonical TGF-β signaling in ovarian cancer , while in cutaneous melanoma, VEPH1 acts protectively by inhibiting TGF-β signaling pathway activation .

How might VEPH1 antibodies facilitate biomarker development in precision oncology?

VEPH1 detection holds promise for cancer stratification and treatment selection:

Research methodology framework:

• Develop standardized immunohistochemistry protocols for clinical application

• Establish scoring systems correlating VEPH1 expression with TGF-β pathway activity

• Integrate with multi-omics data to create predictive biomarker panels

• Conduct prospective validation in patient cohorts receiving TGF-β-targeting therapies

The scientific rationale stems from findings that VEPH1 is highly expressed in invasive ovarian cancer cell lines (OVCA429, ES2, HEY) compared to less invasive lines , suggesting its potential as a marker for aggressive phenotypes. Additionally, VEPH1's role in modulating TGF-β signaling makes it particularly relevant for patient stratification in trials targeting this pathway.

What are the emerging techniques for studying VEPH1 in live cell imaging applications?

Advanced live imaging approaches for VEPH1 research include:

Cutting-edge methodological approaches:

• CRISPR-based endogenous tagging of VEPH1 with fluorescent proteins

• Optogenetic control of VEPH1 expression or localization

• Fluorescent biosensors for monitoring VEPH1-dependent TGF-β activity

• Single-molecule tracking of VEPH1-receptor interactions

• Lattice light-sheet microscopy for high-resolution 3D visualization of VEPH1 dynamics

These techniques would address current knowledge gaps regarding the temporal dynamics of VEPH1's inhibitory effects on SMAD2 release from TβRI, which has been primarily studied using fixed-cell and biochemical approaches .